IO Biotech Announces Participation in Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Nov 11, 2024
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences:
Read more at globenewswire.com
